microRNA 624 (miR-624)

microRNA 624 (miR-624) is a short non-coding RNA belonging primarily to the microRNA family but also sharing classification with small interfering RNAs (siRNAs)[1]. Like other miRNAs, miR-624 functions in the post-transcriptional regulation of gene expression, binding target mRNAs primarily via partial complementarity in the seed region, ultimately repressing protein translation or promoting mRNA degradation[1][3][5][8]. It has been experimentally associated with cell cycle arrest, senescence, and modulation of apoptosis[1][4]. miR-624 directly targets genes such as CASP3 and β-catenin, influencing critical cellular processes including cell survival, proliferation, tumorigenesis, metastasis, and drug resistance in cancer[1][4]. Expression changes of miR-624—such as upregulation in osteosarcoma and downregulation in recurrent prostate cancer—are linked to disease progression and may serve as biomarkers for prognosis and therapeutic response[4]. There is interest in targeting miR-624 with RNA-based drugs to manipulate cancer sensitivity or proliferation, but clinical therapeutics specific to miR-624 remain investigational[4]. Finally, as with other miRNAs, therapeutic targeting of miR-624 poses risks of unintended genetic network disruption[3][4].

Other names

miR-624MIR624hsa-miR-624mir-624MIRN624

Inhibition or mimicry of miR-624 using antisense oligonucleotides or miRNA mimics to modulate gene expression in therapeutic settings. Indirect modulation of cancer-related pathways via targeting downstream effectors of miR-624, e.g., β-catenin, PTPRB, CASP3[1][4].